Rocket Pharmaceuticals (RCKT) Assets (2014 - 2026)

Rocket Pharmaceuticals has reported Assets for 12 years, with the latest figure at $285.4 million in Q1 2026.

• Quarterly Assets fell 39.41% year-over-year to $285.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $285.4 million (down 39.41% YoY) and the FY2025 annual result came in at $330.4 million, down 37.38% from the prior year.
• Assets eased to $285.4 million in Q1 2026 per RCKT's latest filing, from $330.4 million in the prior quarter.
• Over five years, Assets peaked at $566.3 million in Q4 2023 and troughed at $405000.0 in Q2 2022.
• A 5-year average of $286.5 million and a median of $368.0 million in 2025 frame the typical range for Assets.
• The widest YoY moves for Assets: up 75697.66% in 2022, down 70.95% in 2022.
• Over 5 years, Assets stood at $551.8 million in 2022, then rose by 2.63% to $566.3 million in 2023, then fell by 6.82% to $527.7 million in 2024, then slumped by 37.38% to $330.4 million in 2025, then dropped by 13.63% to $285.4 million in 2026.
• According to Business Quant data, Assets over the past three periods registered $285.4 million, $330.4 million, and $368.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.